{"id":3927,"date":"2026-03-09T15:22:26","date_gmt":"2026-03-09T15:22:26","guid":{"rendered":"https:\/\/tradertideinsights.com\/?p=3927"},"modified":"2026-03-09T15:22:26","modified_gmt":"2026-03-09T15:22:26","slug":"hims-stock-jumps-50-as-novo-nordisk-ends-lawsuit-strikes-deal","status":"publish","type":"post","link":"https:\/\/tradertideinsights.com\/?p=3927","title":{"rendered":"Hims stock jumps 50% as Novo Nordisk ends lawsuit, strikes deal"},"content":{"rendered":"
<\/div>\n

Telehealth platforms are becoming a gateway for access to blockbuster weight loss medicines. <\/p>\n

That shift became clearer on Monday after Novo Nordisk dropped its patent infringement lawsuit against digital health provider Hims & Hers.<\/p>\n

The Danish pharmaceutical company has instead agreed to allow Hims to distribute its branded semaglutide drugs through its telehealth platform.<\/p>\n

The move ends a dispute over copycat versions of the obesity drug Wegovy and highlights how drugmakers are increasingly working with online health platforms to reach patients seeking treatments for obesity.<\/p>\n

Legal fight replaced by distribution deal<\/h2>\n

Novo Nordisk confirmed it has withdrawn the legal case it had filed against Hims over alleged patent infringement linked to compounded versions of semaglutide.<\/p>\n

Chief executive Mike Doustdar said on Monday the company had decided to drop the court proceedings while reserving the right to revive them if necessary.<\/p>\n

Under the agreement, Hims will offer Novo Nordisk\u2019s injectable and oral semaglutide medicines on its platform, including Ozempic and Wegovy.<\/p>\n

The treatments will be available at the same price offered through other telehealth platforms.<\/p>\n

Hims has also agreed to stop advertising compounded GLP-1 drugs through its platform or marketing materials.<\/p>\n

Shares of Hims surged as much as 50% in premarket trading, while Novo Nordisk\u2019s Copenhagen-listed stock rose 1.7%.<\/p>\n

Copycat drugs triggered earlier dispute<\/h2>\n

The conflict between the companies escalated earlier this year as demand for semaglutide medicines surged.<\/p>\n

In February, Novo Nordisk said it planned to sue Hims over what it described as mass illegal compounding after the telehealth company introduced a copycat version of the Wegovy pill.<\/p>\n

Hims had announced the product at a price of $49, roughly $100 lower than Novo Nordisk\u2019s branded version sold through its direct to consumer platform, NovoCare.<\/p>\n

The company withdrew the pill after backlash from Novo and warnings from the US Food and Drug Administration.<\/p>\n

The regulator said it would take action against compounding pharmacies offering such products.<\/p>\n

Shortage loophole fuelled copycat sales<\/h2>\n

Hims had generated significant revenue from selling compounded semaglutide using a regulatory loophole in US law.<\/p>\n

The rule allows companies other than the patent holder to produce a drug when the medicine is officially listed as being in shortage.<\/p>\n

Semaglutide experienced supply shortages during the early stages of the weight loss drug boom.<\/p>\n

Novo Nordisk has since expanded manufacturing and said it has resolved those supply constraints.<\/p>\n

Despite that, Hims had continued offering compounded versions, arguing the treatments were personalised prescriptions and therefore legally permitted.<\/p>\n

Semaglutide remains protected by US patents until 2031.<\/p>\n

Telehealth becomes major drug channel<\/h2>\n

The companies had briefly worked together before the dispute.<\/p>\n

Last year, Novo Nordisk partnered with Hims to offer discounted weight loss injections to users of the telehealth platform.<\/p>\n

That collaboration ended after two months when Novo accused Hims of using deceptive marketing practices that could put patient safety at risk.<\/p>\n

Novo now reports more than 600,000 prescriptions for the Wegovy pill since its launch in January.<\/p>\n

Hims said patients currently using compounded semaglutide will have the opportunity to transition to FDA approved medicines when clinicians determine it is appropriate.<\/p>\n

The telehealth provider also said it is speaking with biotechnology firms and pharmaceutical companies that may bring additional therapies to its platform.<\/p>\n

The post Hims stock jumps 50% as Novo Nordisk ends lawsuit, strikes deal<\/a> appeared first on Invezz<\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Telehealth platforms are becoming a gateway for access to blockbuster weight loss medicines. That shift became clearer on Monday after Novo Nordisk dropped its patent infringement lawsuit against digital health provider Hims & Hers.The Danish pharmaceutical company has instead agreed to allow Hims to distribute its branded semaglutide drugs through its telehealth platform.The move ends…<\/p>\n","protected":false},"author":1,"featured_media":3928,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-3927","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock"],"_links":{"self":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/posts\/3927","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3927"}],"version-history":[{"count":0,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/posts\/3927\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=\/wp\/v2\/media\/3928"}],"wp:attachment":[{"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3927"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3927"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradertideinsights.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3927"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}